

# Seven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON: A Multicenter Cohort Study (SEVEN-UP)

Rofagha S, Bhisitkul RB, Boyer DS, et al. *Ophthalmology*. 2013;120:2292-2299.  
doi:http://dx.doi.org/10.1016/j.ophtha.2013.03.046


In this study the researchers assessed the long-term outcomes 7 to 8 years after the initiation of intensive ranibizumab therapy in patients with exudative age-related macular degeneration (AMD).

A total of 65 patients with AMD originally treated with ranibizumab in the phase 3 Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) trial, the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) trial, and the Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (HORIZON) were recruited for a return evaluation.




Approximately 7 years after ranibizumab therapy in the ANCHOR or MARINA trials, one third of the patients demonstrated good visual outcomes, whereas another third had poor outcomes.

## Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Vision Was Calculated for Each Patient; Means Are Shown at Various Timepoints in ANCHOR, MARINA, and HORIZON



At a mean of 7.3 years (range, 6.3-8.5 years) after entry into ANCHOR or MARINA, 37% of study eyes met the primary endpoint of 20/70 or better best-corrected visual acuity (BCVA), with 23% achieving a BCVA of 20/40 or better.

## Distribution of Visual Status (Snellen Equivalent) of Study Eyes in SEVEN-UP Subjects (n=65, n [%]) at Mean of 7.3 Years (6.3-8.5 years)




SEVEN-UP=Seven-Year Observational Update of Macular Degeneration Patients Post-MARINA/ANCHOR and HORIZON Trials.



In a univariate analysis, patients who received 11 injections or more were more likely to gain vision, averaging a gain of 3.9 letters since the HORIZON Month 24 measurement (P < 0.05, Kruskal-Wallis test).

A total of 641 anti-VEGF injections (147 bevacizumab and 494 ranibizumab) were administered in the interval between HORIZON exit and the SEVEN-UP evaluation, representing a mean of 6.8 injections per eye (range, 0-46 injections) during the mean 3.4-year period.

## 5-Year VA Outcomes



## Conclusions

Approximately 7 years after ranibizumab therapy in the ANCHOR or MARINA trials, one third of the patients demonstrated good visual outcomes, whereas another third had poor outcomes. Compared with baseline, almost half of the eyes were stable, whereas one third declined by 15 letters or more. Even at this late stage in the therapeutic course, patients with exudative AMD remain at risk for substantial visual decline.